Search

We present the discovery and validation of a temperate sub-Neptune around the nearby mid-M dwarf TIC 470381900 (TOI-1696), with a radius of $3.09 \pm 0.11 \,R_\oplus$ and an orbital period of $2.5 \,\rm{days}$, using a combination of TESS and follow-up observations using ground-based telescopes. Joint analysis of multi-band photometry from TESS, MuSCAT, MuSCAT3, Sinistro, and KeplerCam confirmed the transit signal to be achromatic as well as refined the orbital ephemeris. High-resolution imaging with Gemini/'Alopeke and high-resolution spectroscopy with the Subaru/IRD confirmed that there are no stellar companions or background sources to the star. The spectroscopic observations with IRD and IRTF/SpeX were used to determine the stellar parameters, and found the host star is an M4 dwarf with an effective temperature of $T_{eff} = 3185 \pm 76\,\rm{K}$ and a metallicity of [Fe/H] $=0.336 \pm 0.060 \,\rm{dex}$. The radial velocities measured from IRD set a $2$-$\sigma$ upper limit on the planetary mass to be $48.8 \,M_\oplus$. The large radius ratio ($R_p/R_\star \sim 0.1$) and the relatively bright NIR magnitude ($J=12.2 \,\rm{mag}$) make this planet an attractive target for further followup observations. TOI-1696b is one of the planets belonging to the Neptunian desert with the highest transmission spectroscopy metric discovered to date, making it an interesting candidate for atmospheric characterizations with JWST., Comment: 25 pages, 18 figures, 3 tables, Submitted to AJ

The increasing number of super-Earths close to their host stars revealed a scarcity of close-in small planets with 1.5-2.0$\,R_\oplus$ in the radius distribution of ${\it Kepler}$ planets. The atmospheric escape of super-Earths by photoevaporation can explain the origin of the observed "radius gap." Many theoretical studies considered the in-situ mass loss of a close-in planet. Planets that undergo the atmospheric escape, however, move outward due to the change in the orbital angular momentum of their star-planet systems. In this study, we calculate the orbital evolution of an evaporating super-Earth with a H$_2$/He atmosphere around FGKM-type stars under a stellar X-ray and extreme UV irradiation (XUV). The rate of increase in the orbital radius of an evaporating planet is approximately proportional to that of the atmospheric mass loss during a high stellar XUV phase. We show that super-Earths with a rocky core of $\lesssim$ 10$\,M_\oplus$ and a H$_2$/He atmosphere at $\lesssim$ 0.03-0.1$\,$au ($\lesssim$ 0.01-0.03$\,$au) around G-type stars (M-type stars) are prone to the outward migration driven by photoevaporation. Although the changes in the orbits of the planets would be small, they would rearrange the orbital configurations of compact, multi-planet systems, such as the TRAPPIST-1 system. We also find that the radius gap and the so-called "Neptune desert" in the observed population of close-in planets around FGK-type stars still appear in our simulations. On the other hand, the observed planet population around M-type stars can be reproduced only by a high stellar XUV luminosity model., 30 pages, 10 figures, accepted for publication in ApJ

We present observations of two bright M dwarfs (TOI-1634 and TOI-1685: $J=9.5-9.6$) hosting ultra-short period (USP) planets, identified by the TESS mission. The two stars are similar in temperature, mass, and radius ($T_\mathrm{eff}\,\approx\,3500$ K, $M_\star\,\approx\,0.45-0.46\,M_\odot$, and $R_\star\approx 0.45-0.46\,R_\odot$), and the planets are both super-Earth-sized ($1.25\,R_\oplus, Comment: 29 pages, 21 figures, 4 tables; AJ in press

Heparin sodium and heparin calcium, which are widely used as anti-coagulants, are known to potentially contain the natural impurity dermatan sulfate (DS). Recently serious adverse events occurred in patients receiving heparin sodium in the US, and a contaminant oversulfated chondroitin sulfate (OSCS) was found to be a cause of the events. To ensure the quality and safety of pharmaceutical heparins, there is need of a physicochemical identification test that can discriminate heparin from the heparin-related substances as well as a sensitive purity test for OSCS. Recently, HPLC with a strong-anion exchange column was proposed as the methods for identifying heparin and determination of OSCS in heparin sodium. Although this method is convenient and easy to perform, the only column suitable for this purpose is the Dionex IonPac AS11-HC column. In this study, we developed alternative identification test and test for OSCS in both heparin sodium and heparin calcium using a weak anion-exchange column. The identification test allowed for separation of heparin from the impurity DS and contaminant OSCS in a shorter time. The purity test provided enough sensitivity, specificity, linearity, recovery and repeatability for OSCS. We believe that our methods will be useful for quality control of pharmaceutical heparins.

Heparin is used as an anticoagulant drug. The anticoagulation process is mainly caused by the interaction of heparin with antithrombin followed by inhibition of anticoagulant factor IIa and factor Xa. The anti-factor IIa and anti-factor Xa activities of heparin are critical for its anticoagulant effect; however, physicochemical methods that can reflect these activities have not been established. Thus, the measurements of anti-IIa and anti-Xa activities by biological assay are critical for the quality control of heparin products. Currently in the Japanese Pharmacopoeia (JP), the activities of heparin sodium and heparin calcium are measured by an anti-Xa activity assay (anti-Xa assay), but anti-IIa activity is not measured. Here, we established an anti-IIa activity assay (anti-IIa assay) and an anti-Xa assay having good accuracy and precision. When samples having a relative activity of 0.8, 1.0 and 1.2 were measured by the established anti-IIa and anti-Xa assays in nine laboratories, good accuracy (100.0-102.8% and 101.6-102.8%, respectively), good intermediate precision (1.9-2.1% and 2.4-4.2%, respectively) and good reproducibility (4.0-4.8% and 3.6-6.4%, respectively) were obtained. The established anti-IIa and anti-Xa assays have similar protocols, and could be performed by a single person without a special machine. The established assays would be useful for quality control of heparin.

Heparin is a sulfated glycosaminoglycan (GAG), which contains N-acetylated or N-sulfated glucosamine (GlcN). Heparin, which is generally obtained from the healthy porcine intestines, is widely used as an anticoagulant during dialysis and treatments of thrombosis such as disseminated intravascular coagulation. Dermatan sulfate (DS) and chondroitin sulfate (CS), which are galactosamine (GalN)-containing GAGs, are major process-related impurities of heparin products. The varying DS and CS contents between heparin products can be responsible for the different anticoagulant activities of heparin. Therefore, a test to determine the concentrations of GalN-containing GAG is essential to ensure the quality and safety of heparin products. In this study, we developed a method for determination of relative content of GalN from GalN-containing GAG in heparin active pharmaceutical ingredients (APIs). The method validation and collaborative study with heparin manufacturers and suppliers showed that our method has enough specificity, sensitivity, linearity, repeatability, reproducibility, and recovery as the limiting test for GalN from GalN-containing GAGs. We believe that our method will be useful for ensuring quality, efficacy, and safety of pharmaceutical heparins. On July 30, 2010, the GalN limiting test based on our method was adopted in the heparin sodium monograph in the Japanese Pharmacopoeia.